Bibliography

Articles

  1. Gross W, Holland PV: Water and ionic regulation in a terrestrial hermit crab. Physiol Zool 1960;33:21-28.
  2. Andrews JR, Holland PV: Sulfur 35 studies in human chrondosarcoma. Am J Roentgenol Radium Nucl Med 1965;94:798-806.
  3. Lemmon WR Jr, Holland PV, Holland JM: The hepatopathy of hypernephroma. Am J Surg 1965;110:487-491.
  4. Rubinson RM, Holland PV, Schmidt PJ, Morrow AG: Serum hepatitis after open-heart operations. J Thorac Cardiovasc Surg 1965; 50:575-581.
  5. Holland PV, Alter HJ, Schmidt PJ: A data retrieval system for blood donor information. Transfusion 1965;5:543-549.
  6. Holland PV, Rubinson RM, Morrow AG, Schmidt PJ: Gamma globulin in the prophylaxis of posttransfusion hepatitis. JAMA 1966;196:471-474.
  7. Lostumbo MM, Holland PV, Schmidt PJ: Isoimmunization after multiple transfusions. N Engl J Med 1966;275:141-144.
  8. Holland PV, Menken M, Berlin NI: Autoimmune hemolytic anemia, acute leukemia, and carcinoma of the lung. Arch Intern Med 1967;120:341-344.
  9. Grindon AJ, Holland PV, Schmidt PJ: Posttransfusion hepatitis. Am Heart J 1967;74:591-594.
  10. Schmidt PJ, Holland PV: Pathogenesis of the acute renal failure associated with incompatible transfusion. Lancet II:1967;1169-1172.
  11. Cooke JV, Holland PV, Schulman NR: Cryoprecipitate concentrates of factor VIII for surgery in hemophiliacs. Ann Intern Med 1968;68:39-47.
  12. Schmidt PJ, Holland PV, Lostumbo MM, Moss KI, Sobota JT: Hemoglobinuria due to anti-rhwl (Cw). Am J Clin Pathol 1968;49:467-471.
  13. Holland PV, Wallerstein RO: Delayed hemolytic transfusion reaction with acute renal failure. JAMA 1968;204:1107-1108.
  14. Golde DW, McGinniss MG, Holland PV: Mechanism of the albumin agglutination phenomenon. Vox Sang 1969;16:465-469.
  15. Purcell RH, Holland PV, Walsh JH, Wong DC, Morrow, AG, Chanock RM: A complement- fixation test for measuring Australia antigen and antibody. J Infect Dis 1969;120:383-392.
  16. Holland PV, Walsh JH, Morrow AG, Purcell RH: Failure of Australia antibody to prevent posttransfusion hepatitis. Lancet II;1969: 553-555.
  17. Gerin JL, Purcell RH, Hoggan MD, Holland PV, Chanock RM: Biophysical properties of Australia antigen. J Virol 1969;4:763-768.
  18. Purcell RH, Walsh JH, Holland PV, Morrow AG: Studies of transfusion associated hepatitis. In: Sanders M, Shaeffer M, eds. Third International Symposium on Medicine and Applied Virology. St. Louis: WH Green Inc, 1969:274-283.
  19. Kueppers F, Holland PV, Weitkamp LR: Albumin Santa Ana: A new inherited variant. Hum Hered 1969;19:378-384.
  20. Purcell RH, Gerin JL, Holland PV, Cline WF, Chanock RM: Preparation and characterization of complement-fixing hepatitis-associated antigen and antiserum. J Infect Dis 1970;121:222-226.
  21. Alter HJ, Holland PV, Schmidt PJ: Hepatitis-associated antigen; to test or not to test. Lancet II 1970;142-143.
  22. Miller WV, Holland PV, Sugarbaker E, Strober W, Waldmann TA: Anaphylactic reaction to IgA; A difficult transfusion problem. Am J Clin Pathol 1970;54:618-621.
  23. Purcell RH, Walsh JH, Holland PV, Morrow AG, Wood S, Chanock RM: Seroepidemiological studies of transfusion-associated hepatitis. J Infect Dis 1971;123:406-413.
  24. Schmidt PJ, Holland PV: Rh null disease. In: Proceedings of the XII Congress of the International Society of Blood Transfusion. Moscow, 1969. 1971;230-233.
  25. Holland PV: Therapeutic use of blood components. In: Conn H, ed. Current Therapy 1971. Philadelphia: WB Saunders, 1971;266-274.
  26. Alter HJ, Holland PV, Purcell RH: Counterelectrophoresis for detection of hepatitis-associated antigen. Methodology and comparison with gel diffusion and complement fixation. J Lab Clin Med 1971;77:1000-1010.
  27. Golde DW, McGinniss MH, Holland PV: Serum agglutinins to commercially prepared albumin. Am J Clin Path 1971;55: 655-658.
  28. Gerin JL, Holland PV, Purcell RH: Australia antigen: large scale purification from human serum and biochemical studies of its proteins. J Virol 1971;7:569-575.
  29. Miller WV, Watson LE, Holland PV, Walsh JH: Evaluation of the effectiveness of hepatitis screening tests. Vox Sang 1971;21:1-10.
  30. Alter HJ, Polesky HF, Holland PV: False positive tests for hepatitis-associated antigen in blood donors caused by antibodies to ruminant serum proteins. J Immunol 1972;108:358-369.
  31. Lander JJ, Holland PV, Alter HJ, Chanock RM, Purcell RH: Antibody to hepatitis associated antigen: Frequency and pattern of response as detected by radioimmunoprecipitation. JAMA 1972;220(8):1070-1082.
  32. Holland PV: Incidence of HBsAg in blood donors. In: Vyas GN, Perkins HA, Schmid R, eds. Hepatitis and Blood Transfusion. New York: Grune & Stratton, 1972:275-276.
  33. Holland PV: Gamma globulin in posttransfusion hepatitis. In: Vyas GN, Perkins HA, Schmid R, eds. Hepatitis and Blood Transfusion. New York: Grune & Stratton, 1972:331-333.
  34. Holland PV, Purcell RH, Smith H, Alter HJ: Subtyping of hepatitis antigen (HBsAg); simplified technique using counterelectrophoresis. J Immunol 1972;109(3):420-425.
  35. Alter HJ, Holland PV, Schmidt PJ, Plotz PH: Gamma globulin for hepatitis Virus B: prevention or extension? Lancet II 1972:1110-1111.
  36. Holland PV, Alter HJ, Purcell RH, Lander JJ, Sgouris JT, Schmidt, PJ: Hepatitis B antigen (HBsAg) and antibody (anti-HBsAg) in cold ethanol fractions of human plasma. Transfusion 1972;12: 363-370.
  37. Alter HJ, Holland PV, Purcell RH, Lander JJ, Feinstone SM, Morrow AG, Schmidt PJ: Posttransfusion hepatitis after exclusion of commercial and hepatitis B antigen positive donors. Ann Intern Med 1972;77:691-699.
  38. Dodd RY, Holland PV, Ni LY, Smith HM, Greenwalt TJ: Hepatitis B antigen (HBsAg): Regional variation in incidence and subtype ratio in the American Red Cross donor population. Am J Epidemiol 1973;97:111-115.
  39. Holland PV, Alter HJ, Purcell RH, Walsh JH, Morrow AG, Schmidt PJ: The infectivity of blood containing the Australia antigen. In: Prier JE, Friedman H, eds. Australia Antigen. Baltimore: University Park Press, 1973:191-203.
  40. Alter HJ, Holland PV, Lander JJ, Feinstone SM, Purcell RH: The Australia antigen and posttransfusion hepatitis. In: Prier JE, Friedman H, eds. Australia Antigen. Baltimore: University Park Press, 1973:205-211.
  41. Whitaker J, Holland PV, Alter HJ, Engel WK: Idiopathic inflammatory myopathy: failure to detect Hepatitis B antigen in serum and muscle. Arch Neurol 1973;28:410-411.
  42. Salisbury KW, Plotz PH, Holland PV, Steinberg AD, Peppercorn M: Serologic abnormalities in systemic lupus erythematosus associated with viral hepatitis and tuberculosis. Arthritis Rheum 1973;6:406-410.
  43. Lewis TL, Alter HJ, Chalmers TC, Holland PV, Purcell RH, Alling DW, Young D, Frenkel LD, Lee SL, Lamson ME: A comparison of the frequency of hepatitis B antigen and antibody in hospital and non-hospital personnel. N Engl J Med 1973;289(13):647-651.
  44. Purcell RH, Wong DC, Alter HJ, Holland PV: A microtiter solid-phase radioimmunoassay for Hepatitis B antigen. Appl Microbiol 1973;26:478-484.
  45. Alter HJ, Holland PV, Purcell RH, Gerin J: The Ausria test: critical evaluation of sensitivity and specificity. Blood 1973;42:947-957.
  46. Feinman SV, Berris B, Wrobel DM, Sinclair JC, Alter HJ, Holland PV: Relation of Hepatitis-B-antigen subtypes in symptom-free carriers to geographical origin and liver abnormalities. Lancet II 1973:867-869.
  47. Le Bouvier GL, Bancroft WH, Holland PV: On the rare ayr phenotype of hepatitis-B antigen. Intervirology 1973;1:505-508.
  48. Peters CJ, Reeves WC, Holland PV, Alter HJ: Antigenic subtypes of hepatitis B antigen in Panama. Am J Epidemiol 1974;9:375-380.
  49. Gold JWM, Alter HJ, Holland PV, Gerin JL, Purcell RH: Passive hemagglutination assay for antibody to subtypes of hepatitis B antigen. J Immunol 1974;112:1100-1106.
  50. Aach RD, Alter HJ, Hollinger FB, Holland PV, Lander JJ, Melnick JL, Weiler JM: Risk of transfusing blood containing antibody to Hepatitis-B surface antigen. Lancet II 1974:190-193.
  51. Alter HJ, Holland PV, Purcell RH: Viral hepatitis-Light at the end of the tunnel. JAMA 1974;229:293-294.
  52. Purcell RH, Gerin JL, Almeida JB, Holland PV: Radioimmunoassay for the detection of the core of the Dane particle and antibody to it. Intervirology 1974;2:231-243.
  53. Kulesza A, Mikulska B, Holland PV, Nowoslawski A: An outbreak of nonparenterally transmitted hepatitis type B. In: Proceedings VII International Congress Infectious Parasitic Diseases. Warsaw. 1974:155-157.
  54. Pintera J, Vacl J, Holland PV, Alter HJ: Some approaches to deciding HBsAg (Australia antigen) positivity by counter immunoelectrophoresis. Blut 1974;29:165-171.
  55. Pintera J, Vacl J, Holland PV, Alter HJ. Effectiveness of additionally incubated counterimmunoelectrophoresis screening for Hepatitis B antigen. Scripta Medica 1974;47:347-55.
  56. Pintera J, Vacl J, Holland PV, Alter HJ: Distribution of HBsAg subtypes among HBsAg positive blood donors of South Moravian region. Scripta Med 1974;47:357-362.
  57. Alter HJ, Chalmers TC, Freeman BM, Lunceford JL, Lewis TL, Holland PV, Pizzo PA, Plotz PH, Meyer WJ III: Health care workers positive for hepatitis B surface antigen: Are their contacts at risk? N Engl J Med 1975;292:454-457.
  58. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV: Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975;292:767-770.
  59. Holland PV, Alter HJ: The clinical significance of hepatitis B virus antigens and antibodies. Med Clin NA 1975;59:849-855.
  60. Gerin JL, Faust RM, Holland PV: Biophysical characterization of the adr subtype of hepatitis B antigen and preparation of anti-r sera in rabbits. J Immunol 1975;115:100-105.
  61. Holland PV, McGinniss MH: Laboratory and clinical significance of the albumin agglutination phenomenon. In: Sgouris JT, Rene A, eds. Proceedings of the Workshop on Albumin. Washington DC: G.P.O. 1975:333-337.
  62. Alter HJ, Holland PV, Purcell RH: The emerging pattern of post- transfusion hepatitis. Am J Med Sci 1975;270:329-334.
  63. Holland PV, Madalinski K: Podtypy antygenu hepatitis B. Pol Arch Med Wewn 1975;2(2):105-111.
  64. Holland PV: Hepatitis B antigen subtypes: history, significance and immunogenicity. Am J Med Sci 1975;270:161-164.
  65. Alter HJ, Purcell RH, Holland PV, Feinstone SM, Morrow AG, Moritsugu Y: Clinical and serological analysis of transfusion-associated hepatitis. Lancet II 1975:838-841.
  66. Alter HJ, Barker LF, Holland PV: Hepatitis B immune globulin: Evaluation of clinical trials and rationale for usage. N Engl J Med 1975;293:1093-1094.
  67. Holland PV, Alter HJ: Current concepts of viral hepatitis. In: Drew WL, ed. Viral Infections:A Clinical Approach. Philadelphia: FA Davis Co, 1976;7:189-211.
  68. Gerety RJ, Poplack DG, Hoofnagle JH, Blaese RM, Holland PV, Barker LF: Hepatitis B virus infection in the Wiskott-Aldrich Syndrome. J Ped 1976;88:561-564.
  69. Gloskowska-Moraczewska Z, Holland PV, Madalinski K, Kalinowska B: Podtypy antygenu powierzghniowego wirusa hepatitis B wystepujace w polsce. Acta Haemat Pol VII 1976;3:189-193.
  70. Courouce AM, Holland PV, Muller JY, Soulier JP, eds. HBs Antigen Subtypes. Proceedings of International Workshop on HBs Antigen Subtypes. 1976. 158 p.
  71. Alter HJ, Seeff LB, Kaplan PM, McAuliffe VJ, Wright EC, Gerin JL, Purcell RH, Holland PV, Zimmerman HJ: Type B hepatitis: The infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 1976;295: 909-913.
  72. Koziol DE, Alter HJ, Kirchner JP, Holland PV: The development of HBsAg-positive hepatitis despite the prior existence of antibody to HBsAg. J Immunol 1976;117(6):2260-2262.
  73. Vyas GN, Roberts I, Peterson DL, Holland PV: Nonspecific test reactions for antibodies to hepatitis B surface antigen in chronic HBsAg carriers. J Lab Clin Med 1977;89(2):428-432.
  74. Dienstag JL, Feinstone SM, Purcell RH, Wong DC, Alter HJ, Holland PV: non-A, non-B posttransfusion hepatitis. Lancet I 1977:560-562.
  75. Madalinski K, Holland PV, Moraczewska Z, Kalinowska B, Alter HJ: Subtypes of HBsAg in eastern and southeastern Europe. Vox Sang 1977;32:224-229.
  76. Holland PV: The use of Hepatitis B immune globulin (HBIG) in the prevention of hepatitis. Act Haemat Pol VIII 1977;2:97-102.
  77. Alter HJ, Purcell RH, Gerin JL, London WT, Kaplan PM, McAuliffe VJ, Wagner J, Holland PV: Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen. Infection and Immunity 1977;16:928-933.
  78. Miller WV, Busch S, Garratty G, Harris JP, Holland PV, McCullough J, Shaw JF, Tourault MA, Widmann FK, Solomon JM: Technical Manual, AABB 1977: 7th Ed. 390 p.
  79. Moraczewska Z, Madalinski K, Holland PV: Simultaneous presence in serum of HBsAg and Anti-HBs of different specificities. Intervirology 1978;9:89-92.
  80. Reys LL, Purcell RH, Holland PV, Alter HJ: The relationship between hepatitis B virus infection and hepatic cell carcinoma in Mozambique. Trop Geogr Med 1977;29:251-256.
  81. Whitney RA, Ganaway JR, Allen AM, Alter HJ, Purcell RH, Holland PV: Failure to transmit human viral hepatitis types A and B to the congenitally athymic nude mouse. Lab Animal Sci 1978;27:1031.
  82. Alter HJ, Purcell RH, Holland PV, Popper H: Transmissible agent in “non-A, non-B” hepatitis. Lancet 1 1978:459-463.
  83. Alter HJ, Tabor E, Meryman HT, Hoofnagle JH, Kahn RA, Holland PV, Gerety RJ, Barker LF: Transmission of hepatitis B virus infection by transfusion of frozen-deglycerolized red blood cells. New Engl J Med 1978;298:637-642.
  84. Seeff LB, Wright EC, Zimmerman HJ, Alter HJ, Dietz AA, Felsher BF, Finkelstein JD, Garcia-Pont P, Gerin JL, Greenlee HB, Hamilton J, Holland PV: Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Ann of Int Med 1978;88:285-293.
  85. Davey RJ, Tourault MA, Holland PV: The clinical significance of anti-H in an individual with the Oh (Bombay) phenotype. Transfusion 1978;18:738-742.
  86. Kolins J, Holland PV, McGinniss MH: Multiple red cell antigen loss in acute granulocytic leukemia. Cancer 1978;42:2248-2253.
  87. Alter HJ, Purcell RH, Feinstone SN, Holland PV, Morrow AG: Non-A, non-B hepatitis: A review and interim report of an ongoing prospective study. Proceedings of Second UCSF Symposium on Viral Hepatitis. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis. Philadelphia: Franklin Institute Press, 1978:359-369.
  88. Holland PV: Discussion of paper by Dr. M Goldfield: Control of posttransfusion hepatitis. Proceedings of Second UCSF Symposium on Viral Hepatitis. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis. Philadelphia. Franklin Institute Press, 1978:415-417.
  89. Klein HG, Alter HJ, Holland PV: Postexposure immunoglobulin prophylaxis of hepatitis B: A comparison of two dosage schedules. Proceedings of Second UCSF Symposium on Viral Hepatitis. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis. Philadelphia. Franklin Institute Press, 1978:483-486.
  90. Courouce AM, Holland PV: Summary of Workshop A2 – HBsAg and its subtypes. Proceedings of Second UCSF Symposium on Viral Hepatitis. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis. Philadelphia: Franklin Institute Press, 1978:649-654.
  91. Spiro TE, Jaffe R, Holland PV, Alter HJ: A Study of street heroin lots for the presence of the hepatitis-B surface antigen. Drug and Alcohol Dependence 1978;3:393-397.
  92. Miller LH, McGinniss MH, Holland PV, Sigmon P: The Duffy group phenotype in American Blacks infected with plasmodium vivax in Vietnam. Amer J Trop Med & Hygiene 1978;27:1069-1072.
  93. Davey RJ, Gustafson M, Holland PV: Accelerated immune red cell destruction in the absence of serologically detectable alloantibodies. Transfusion 1980;20:348-353.
  94. Klein HG, Faltz LA, McIntosh CL, Applebaum FR, Deisseroth AB, Holland PV: Surgical hypothermia in a patient with a cold agglutinin: Management by plasma exchange. Transfusion 1980;20: 354-357.
  95. Milich DR, Vyas GN, Holland PV, Courouce-Pauty AM, Sampliner RE: Plasmapheresis of hepatitis B surface antigen carriers. Acta Haemat Pol 1980;XI:73-78.
  96. Alter HJ, Holland PV, Purcell RH: The current status of posttransfusion hepatitis. Pathobiology Annual 1980;10:135-156.
  97. Holland P, Golosova T, Szmuness W, Ketiladze E, Purcell R, Budnitskaya P, Gerety R, Voroshieva T, Harley E, Burlev V, Alter H, Margolina A, Lubashevskaya E: Viral hepatitis markers in Soviet and American blood donors. Transfusion 1980;20:504-510.
  98. Holland PV: Transmission Patterns. In: Genetics for Blood Bankers, AABB. Washington DC. 1980;19-29.
  99. Chandeysson PL, Flye WM, Simpkins SS, Holland PV: Delayed hemolytic transfusion reaction caused by anti-P1 antibody. Transfusion 1981;21:77-82.
  100. Holland PV, Klein HG: Effects of pheresis. International Forum. Vox Sang 1981;39:176-177.
  101. Holland PV: Blood transfusions: Benefits and risks. NIH publication no. 81-1949, 1981.
  102. Madalinski K, Holland PV, Moraczewska Z, Nowoslawski A: Preparation of monospecific subtyping reagents for hepatitis B surface antigen (HBsAg). Mat Med Pol 1979;11(4):311-316.
  103. Holland PV, Bancroft W, Zimmerman H: Post-transfusion viral hepatitis and the TTVs. New Engl J Med 1981;304:1033-1035.
  104. Widmann FK, Barnes A, Case J, Garratty G, Holland PV, McCullough JJ, Nusbacher J, Peterson EE, Steane SM, Wallace ME, Wells J: Technical Manual, AABB. 8th edition. Washington DC, 1981. 442 p.
  105. Alter HJ, Purcell RH, Holland PV, Alling DW, Koziol DE: Donor transaminase (ALT) and recipient hepatitis: Impact on blood transfusion services. JAMA 1981;246:630-634.
  106. Coles SM, Klein HG, Holland PV: Alloimmunization in two multi-transfused patient populations. Transfusion 1981;21:462-466.
  107. Holland PV: Syphilis testing of blood donors. International Forum. Vox Sang 1981;41:185-186.
  108. Hollinger B, Alter HJ, Holland PV, Aach RD: Non-A, non-B posttransfusion hepatitis in the U.S. In: Garety R, ed. Viral Hepatitis. New York: Academic Press, 1981:49-70.
  109. Holland PV, Alter HJ: Non-A, non-B viral hepatitis. Human Path 1981;12:1114-1122.
  110. Holland PV: Other adverse effects of transfusion: In: Petz LD, Swisher S, eds. Clinical practice of blood transfusion. Livingston NY. 1981:783-803.
  111. Gadek JE, Klein H, Holland PV, Crystal RG et al: Replacement therapy of alphal-antitrypsin deficiency: Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981;68:1158-1165.
  112. Holland PV: Active and passive immunoprophylaxis of hepatitis B virus infection. Ital J Gastroenterol 1982;14:51-55.
  113. Bove JR, Oberman HA, Holland PV, Ishak KG, Peck C, Shorey J: Report of the ad hoc committee on ALT testing. Transfusion 1982;22:4-5.
  114. Holland PV: Available means to further reduce posttransfusion hepatitis. In: Szmuness W, Alter HJ, Maynard JE, eds. Viral Hepatitis: 1981 International Symposium. Philadelphia: Franklin Institute Press, 1982:563-571.
  115. Holland PV: Non-A, non-B viral hepatitis. Ital J Gastroenterol 1982;14:111-113.
  116. Alter HJ, Holland PV: The 1981 International Symposium on Viral Hepatitis. Ital J Gastroenterol 1982;14:124-126.
  117. Davey RJ, Holland PV: Do you think the crossmatch with donor red cells can be omitted when the serum of a patient has been tested for the presence of red cell alloantibodies with a cell panel? International Forum. Vox Sang 1982;43:151-168.
  118. Alspach JG, Holland PV, McKeon KL: Joint physician-nurse committee ensures safe transfer of tasks. Hospitals 1982;56:54-55.
  119. Holland PV: The value of ALT-GPT screening of blood donors. International Forum. Vox Sang 1983;44:54-56.
    Holland PV: Strategies for further reduction of transfusion associated hepatitis. In: Overby L, Dienhardt F, Dienhardt J, eds. Viral Hepatitis: Second International Max von Pettenkofer Symposium. New York: M Dekker, 1983:235-237.
  120. Holland PV: Prophylaxis of viral hepatitis: Transfusion transmitted disease and the hepatitis B vaccine. In: Verme G, Bonino F, Rizzetto M, eds. Viral Hepatitis and Delta Infection. New York: A R Liss, 1983:357-367.
  121. McGinniss MH, MacLowry JD, Holland PV: Acquisition of K:1-like antigen during terminal sepsis. Transfusion 1984;24:28-30.
  122. Holland PV: Costs and benefits of radioimmunoassay in the diagnosis and prophylaxis of viral hepatitis. In: Albertini A, Ekins RP, Galen RS, eds. Cost/benefit and predictive value of radioimmunoassay. Amsterdam: Elsevier Science Publishers, 1984: 213-224.
  123. Holland PV: Strategies for active and passive prophylaxis to the hepatitis B virus – the adult. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. Orlando: Grune and Stratton, 1984:527-532.
  124. Alter HJ, Holland PV: Indirect tests to detect the non-A, non-B hepatitis carrier state. Ann Int Med 1984;101:859-861.
  125. Holland PV: Hepatitis B Surface Antigen and Antibody (HBsAg/ Anti-HBs). In: Gerety RJ, ed. Hepatitis B. Orlando: Academic Press, 1985:5-25.
  126. Carlson J, Bryant ML, Hinrichs S, Yamamoto J, Levy N, Yee J, Higgins J, Levine A, Holland PV, Gardner MB, Pedersen NC: AIDS serology testing in low and high risk groups. JAMA 1985;253: 3405-3408.
  127. Leitman SF, Holland PV: Irradiation of blood products: Indications and guidelines. Transfusion 1985;25:293-300.
  128. Holland PV, Richards CA, Teghtmeyer JR, Douville CM, Carlson JR, Hinrichs SH, Pederson NC: Anti-HTLV-III testing of blood donors: reproducability and confirmability of commercial test kits. Transfusion 1985;25:395-397.
  129. Holland PV: Transfusion-associated graft-versus-host disease: Prevention using irradiated blood products. In: Garratty G, ed. Current concepts in transfusion therapy. Arlington, VA: AABB, 1985:295-315.
  130. Koziol DE, Holland PV, Alling DW, Melpolder JC, Solomon RE, Purcell RH, Hudson LM, Shoup FJ, Krakauer H, Alter HJ: Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Int Med 1986; 104:488-495.
  131. Ward JW, Deppe DA, Sampson S, Perkins H, Holland PV, Fernando L, Feorino PM, Thompson P, Kleinman S, Allen JR: Risk of human immunodeficiency virus infection from blood donors who later developed the acquired immunodeficiency syndrome. Ann Int Med 1987;106:61-62.
  132. Holland PV: The human immunodeficiency virus and the spectrum of its infection: From asymptomatic antibody positive state to acquired immunodeficiency syndrome (AIDS). Saluggia (Vercelli): Sorin Biomedica S.p.A., 1987:1-67.
  133. Holland PV, Schmidt PJ, eds. Standards for blood banks and transfusion services. 12th ed. Arlington, VA:AABB, 1987:1-52.
  134. Holland PV: Informing the transfusion recipient: How much is enough? In: Smith DM, Carlson KB, eds. Current scientific/ethical dilemmas in blood banking. Arlington, VA: AABB, 1987;15-27.
  135. Watson-Williams EJ, Yee JL, Carlson JR, Mertens SC, Holland PV, Sinor L, Plapp FV: Solid phase red cell adherence immunoassay for anti-HIV 1: A simple, rapid and accurate method for donor screening. Transfusion 1988;28:184-186.
  136. Holland PV: Why a new standard to prevent Creutzfeldt-Jakob Disease? Editorial. Transfusion 1988;28:293-4.
  137. Perkins CI, Kizer KW, Hughes MJ, Holland PV, Lloyd JC: Anti-HIV seroprevalence in California blood and plasma donors. West J Med 1988;149:620-622.
  138. Holland PV: Why test autologous units? In: Maffei LM, Thurer RL, eds. Autologous blood transfusion: Current issues. Arlington, VA:AABB, 1988:167-176.
  139. Holland PV: Prevention of transfusion-associated graft-versus-host disease (GVHD). Arch Path Lab Med 1989;113:285-291.
  140. Holland PV: The diagnosis and management of transfusion reactions and other adverse effects of transfusion. In Petz LD, Swisher SN, eds. Clinical Practice of Transfusion Medicine. Second ed. New York: Churchill Livingstone, 1989:713-736.
  141. Aoki SK, Holland PV: Lyme disease – another transfusion risk? Transfusion 1989;29:646-650.
  142. Holland PV, ed. Standards for blood banks and transfusion services. 13th ed. Arlington, VA:AABB, 1989;1-55.
  143. Ward JW, Bush TJ, Perkins HA, Lieb LE, Allen JR, Goldfinger D, Samson SM, Pepkowitz SH, Fernando LP, Holland PV, Kleinman SH, Grindon AJ, Garner JL, Rutherford GW, Holmberg SD: The natural history of transfusion-associated infection with human immunodeficiency virus: Factors influencing the rate of progression to disease. New Engl J Med 1989;321:947-952.
  144. Mosley JW, Aach RD, Hollinger FB, Stevens CE, Barbosa LH, Nemo GJ, Holland PV, Bancroft WH, Zimmerman HJ, Kuo G, Choo Q-L, Houghton M: Non-A, non-B hepatitis and antibody to hepatitis C virus. JAMA 1990;263;77-78.
  145. Samson S, Busch M, Ward J, Garner J, Salk S, Fernando L, Holland P, Rutherford G, Benjamin R, Perkins H: Identification of HIV-infected transfusion recipients: The utility of cross-referencing previous donor records with AIDS case reports. Transfusion 1990;30:214-218.
  146. Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV: The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Int Med. 1990;112:958-960.
  147. Holland PV: Looking ahead-Trends for the 1990’s. Nance SJ, ed. Transfusion Medicine in the 1990’s. Arlington, VA: American Association of Blood Banks, 1990;253-266.
  148. Richards C, Holland P, Kuramoto K, Douville C, Randell R: Prevalence of antibody to hepatitis C virus in a blood donor population. Transfusion 1991;31:109-113.
  149. Holland PV, Nishioka K, Seidl S: Anti-HCV testing – Implications for blood donors and transfusion recipients. In: Hollinger FB, ed. Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease, 1991;874-879.
  150. Hayashi PH, Flynn N, McCurdy SA, Kuramoto IK, Holland PV, and Zeldis JB: Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991;33:177-180.
  151. Robertson EF, Weare JA, Randell R, Holland PV, Madsen G, and Decker RH: Characterization of a reduction-sensitive factor from human plasma responsible for apparent false activity in competitive assays for antibody to hepatitis B core antigen. J Clin Microbiol 1991;29 (3):605-610.
  152. Holland PV: Screening of HIV in blood banks in the U.S.A. AIDS J 1991;3 (2):145-147.
  153. Holland PV: Looking ahead in blood banking-trends for the 1990’s. In: Giornate Medico Chirurgiche Internazionali, Edizioni Minerva Medica, Torino 1991.
  154. Holland PV: Blood donors with anti-HCV – true or false positive? La Trasfusione del Sangue, 1991;36:299-304.
  155. Randell, RL, Holland PV: Transfusion-associated hepatitis. In: Smith DM, Dodd RY, eds. Transfusion transmitted infections, 1991;115-131.
  156. Paglieroni T, Holland PV: Effects of serial plasmapheresis on serum IgA levels in IgA-deficient blood donors with IgA suppressor T cells. Transfusion 1992;32:139-144.
  157. Zeldis JB, Jain S, Kuramoto IK, Richards C, Sazama K, Samuels S, Holland PV, Flynn N: Seroepidemiology of viral infections among intravenous drug users in Northern California. West J Med 1992;156:30-35.
  158. Kalter SS, Heberling RL, Barry JD, Kuramoto K, Holland PV, Sazama K: Detection of antibody to immunodeficiency viruses by dot immmunobinding assay. J Clin Micro 1992;30:993-995.
  159. Kotwal GJ, Baroudy BM, Kuramoto IK, McDonald FF, Schiff GM, Holland PV, Zeldis JB: Detection of acute hepatitis C virus infection by ELISA using a synthetic peptide comprising a structural epitope. Proc Natl Acad Sci USA 1992;89;4486-4489.
  160. Aoki S, Holland PV: The safety of blood and blood products. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. AIDS: Etiology, Diagnosis, Treatment and Prevention, 3rd ed. 1992;463-470.
  161. Sazama K, Kuramoto IK, Holland PV, Courouce A-M, Gallo D, Hanson CV: Detection of antibodies to human immunodeficiency virus type 2 (HIV-2) in blood donor sera using United States assay methods for anti-HIV type 1. Transfusion 1992;32:398-401.
  162. Lee JH, Paglieroni TG, Holland PV, Zeldis JB: Chronic hepatitis B virus infection in an anti-HBc-nonreactive blood donor: Variant virus or defective immune response? Hepatology 1992;16:24-30.
  163. Wun T, Paglieroni T, Sazama K, Holland PV: Detection of plasmapheresis-induced platelet activation using monoclonal antibodies. Transfusion 1992;32:534-540.
  164. Kleinman S, Alter H, Busch M, Holland P, et al: Increased detection of HCV infected blood donors using a multiple antigen HCV enzyme immunoassay. Transfusion 1992;32:805-813.
  165. Busch MP, Holland PV: Idiopathic CD4+ T-lymphocytopenia (ICL) and the safety of blood transfusions: What do we know and what should we do? Transfusion 1992;32:800-804.
  166. Holland PV: Transfusion Transmitted Infectious Diseases. Florida J Med 1993;80:33-36.
  167. Zhang HY, Kuramoto IK, Mamish D, Sazama K, Holland PV, Zeldis JB: Hepatitis C virus in blood samples from volunteer donors. J Clin Micro 1993;31:606-609.
  168. Stroncek DF, Holland PV, Bartch G, et al: Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program (NMDP). Blood 1993;81:1940-1946.
  169. Aoki SK, Finegold D, Kuramoto IK, Douville C, Richards C, Randell R, Fernando L, Holland PV, Zeldis JB: Significance of anti-HBc in blood donors as determined by their serologic response to the hepatitis B vaccine. Transfusion 1993;33:362-367.
  170. Aoki SK, Holland PV, Fernando LP, Kuramoto IK, Anderson S, Sazama K, Schoening V, Johnson P, Wilber JC, Fenner L, Alter HJ: Evidence of hepatitis in patients transfused with blood components containing antibody to hepatitis C. Blood 1993;82:1000-1005.
  171. Reesink HW, Dodd RY, Leikola J, Holland PV, Whyte G, Hewitt P, Kühnl P, Dominka TH: How far shall we go in the predonation selection of blood donors to safeguard patients for blood transfusion related infections? International Forum; Vox Sang 1993;65:1-9.
  172. Robinson CB, Martin WR, Ratliff JL, Holland PV, Wu R, Cross CE: Elevated levels of serum mucin-associated antigen in adult patients with cystic fibrosis. Am Rev Respir Dis 1993;148:385-389.
  173. Sazama K, Holland PV: Transfusion-induced graft-versus-host disease. In: Garratty G, ed. Immunobiology of transfusion medicine. New York, Marcel Dekker, Inc. 1993;631-656.
  174. Holland PV: Blood establishments: How AABB standards are created. In: MacPherson JL, ed. The nation’s blood supply: Is absolute safety achievable? Washington DC, CCBC 1993;7-10.
  175. Schupper H, Hayashi P, Scheffel J, Aceituno S, Paglieroni T, Holland PV, Zeldsi JB: Peripheral blood mononuclear cell responses to recombinant hepatitis C virus antigens in patients with chronic hepatitis C. Hepatology 1993;18:1055-1060.
  176. Busch MP, Valinsky JE, Paglieroni T, Prince HE, Crutcher GJ, Gjerset GF, Operskalski EA, Charlebois E, Bianco C, Holland PV, Petersen LR, Hollingsworth CG, Mosley JW: Screening of blood donors for idiopathic CD4+ T-lymphocytopenia. Transfusion 1994;34:192-197.
  177. Holland PV: Overview: Diagnostic tests for viral infections transmitted by blood. Nucl Med Biol 1994;21:407-417.
  178. Hayashi PH, Fernando L, Schuch MD, Koldinger R, Kelly PB, Ingram M, DeFelice R, Marriott SE, Holland PV, Zeldis JB: Alerts, notices and case reports: Seronegative hepatitis C virus liver failure following transplantation of a cadaveric heart. West J of Med 1994;160:368-371.
  179. Wun T, Paglieroni T, Holland PV: Prolonged circulation of activated platelets following plasmapheresis. J Clin Apheresis 1994;9:10-16.
  180. Aoki SK, Kuramoto IK, Anderson S, Schoening V, Rodriguez R, Fernando L, Sazama K, Holland PV: Evidence that use of a second-generation hepatitis C antibody assay prevents additional cases of transfusion-transmitted hepatitis. J Vir Hepatitis 1994;1:73-77.
  181. Holland PV, Paglieroni T: Circannual variation in lymphocyte subsets, revisited. Transfusion 1994;34:512-516.
  182. Shimizu M, Holland PV: Toward zero occurrence of post-transfusion hepatitis: Summary of a specialty session. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease; 8th International Symposium on Viral Hepatitis and Liver Disease; 1994:507-508.
  183. Brecher ME, Hogan JJ, Holland PV, et al: Platelet bacterial contamination and the use of a chemiluminescence-linked univeral bacterial ribosomal RNA gene probe. Transfusion 1994;34:750-755.
  184. Holland PV: Safety in the blood bank. In Nance ST, ed. Blood Supply: Risks, perceptions and prospects for the future. Bethesda, MD: American Association of Blood Banks, 1994;61-78.
  185. Anderson SC, Kuramoto IK, Holland PV, et al: Comparison of two second-generation anti-hepatitis C virus ELISA on 21,431 US blood donor samples. J Vir Hepatitis 1995;2:55-61.
  186. Paglieroni TG, Ward J, Holland PV: Changes in peripheral blood CD5 (Bla) B-cell populations and autoantibodies following blood transfusion. Transfusion 1995;35:189-198.
  187. Smith EN, Holland PV, Holliman SM, Fuller MJ: Staff costs associated with the implementation of a comprehensive compliance program in a community blood center. Transfusion 1995;35:679-682.
  188. Jenner PW, Holland PV: Diagnosis and management of transfusion reactions. In: Clinical Practice of Transfusion Medicine, 3rd Ed., Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG, eds. 1995;905-929.
  189. Holland PV. Notification and counseling of blood donors. Vox Sang 1996;70 (suppl 3):46-49.
  190. Okamoto H, Kobata S, Tokita H, Inoue T, Woodfield G, Holland PV, et al: A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene. J Virol Methods 1996; 57:31-45.
  191. Holland PV: Strategies for prevention of viral hepatitis in the United States. In: National Strategies for Viral Hepatitis and Hepatocellular Carcinoma in Different Countries. Tanikawa K, Suzuki H, Holland PV, eds. International Hepatology Communications 1996;5:3-9.
  192. Holland PV: Viral infections in the blood supply. N Engl J Med 1996;334:1734-1735.
  193. Mast EE, Favorov MO, Shapiro CN, Holland PV, et al: Hepatitis E virus infection in the Americas. In: Enterically-Transmitted Hepatitis Viruses, Proceedings of the International Symposium on Enterically-Transmitted Hepatitis Viruses, Paris, École du Val-de-Grâce, 1995; Buisson Y, Coursaget P, Kane M, eds., 1996; 282-293.
  194. Holland PV, Barrera JM, Ercilla MG, et al: Genotyping hepatitis C virus isolates from Spain, Brazil, China, and Macau by a simplified PCR method. J Clin Micro, 1996;34:2372-2378.
  195. Holland PV: Informed consent for transfusion recipients: How much is enough? In: Trigger Factors in Transfusion Medicine, Proceedings of the Twentieth International Symposium on Blood Transfusion, Groningen 1995. Sibinga CThS, Das PC, Snyder EL, eds. Kluwer Academic Publishers, 1996:17-24.
  196. Busch MP, Collier A, Holland, PV et al: The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview. Transfusion 1996;36:854-859.
  197. Fuller MJ, Holland PV: Comprehensive reimbursement model: An alternative to fee-for-service reimbursement by blood centers. Trans Med Reviews 1997:11:38-43.
  198. Holland PV, Spence RK, Lewis L: Making donated blood safer — and less necessary. Patient Care 1997;31:181-196.
  199. Holland PV: Consent for transfusion: Is it informed? Trans Med Rev 1997;11:274-285.
  200. Holland PV: Screening blood donors for infectious disease: Current status and perspectives. Central European Journal of Immunology 1997;22:167-169.
  201. Fuller MJ, Holland PV: The 90’s Paradox: QA efforts reduce total quality. Transfusion Science, 1997;18:597-602.
  202. Mast EE, Kuramoto I, Schoening V, Holland PV, et al: Prevalence of and risk factors for antibody to hepatitis E virus seroreactivity among blood donors in Northern California. J Infect Dis 1997;176:34-40.
  203. Holland PV: Risk of viral hepatitis from blood: Status report. In Viral Hepatitis and Liver Disease, Proceedings of IX Triennial International Symposium, Rome, Italy, April 1996; Rizzetto M, Purcell RH, Gerin JL, Verme G; Edizioni Minerva Medica 1997; 617-619.
  204. Mast EE, Alter MJ, Holland PV, Purcell RH: Evaluation of assays for antibody to hepatitis E virus by a serum panel. In Viral Hepatitis and Liver Disease, Proceedings of IX Triennial International Symposium, Rome, Italy, April 1996; Rizzetto M, Purcell RH, Gerin JL, Verme G; Edizioni Minerva Medica, 1997; 327-330.
  205. Fuller M, Holland PV: The optimist’s scenario: Blood Centre opportunities currently available in the U.S.A. In: European Transfusion Medicine, Proceedings of the ISBT 5th Regional (4th European) Congress, Venezia, July, 1995; U Rossi, AL Massaro, G Sciorelli, eds.; 1136-1138.
  206. Gresens CJ, Holland PV: Current risks of viral hepatitis from blood transfusion. J Gastro and Hepatology 1998;13:443-449.
  207. Kemper M, Witt D, Madsen T, Kuramoto K, Holland PV: The effects of dilution on the outcome of pooled plasma testing with HIV type 1 (HIV-1) RNA genome amplification as compared to the outcome of individual-unit testing with other HIV-1 markers. Transfusion 1998;38:469-472.
  208. Holland PV: Post-transfusion hepatitis: Current risks and causes. Vox Sang 1998;74 (Suppl.2):135-141.
  209. Holland PV: Screening blood donors for infectious disease: Current status and perspectives. Hepatologia Polska, Advances in Hepatitis Research 1998;5(suppl.1):89-92.
  210. Paglieroni TG, Perez R, Katznelson S, Muto K, Chang T, Scott S, MacKenzie MR, Holland PV: Donor cell induced CD69 expression and intracellular IL-2 and IL-4 production by peripheral blood lymphocytes isolated from kidney transplant recipients. Human Immunology 1999;60:41-56.
  211. Lee TH, Paglieroni T, Ohto H, Holland PV, Busch MP: Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent long-term microchimerism in severe trauma patients. Blood 1999; 93:3127-3139.
  212. Kopko PM, Holland PV: Process improvement in transfusion medicine: One blood center’s approach. Arch Path Lab Med 1999;123:569-575.
  213. Kopko PM, Holland PV: Transfusion related acute lung injury. Brit J of Haem 1999;105:322-329.
  214. Lara PN, Coe TL, Zhou H, Fernando L, Holland PV, Wun T: Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Amer J Med 1999;107:573-579.
  215. Holland PV: Leukocyte reduction. Sacramento Medicine 2000;10-11.
  216. Holland PV: Risk Management in the United States. In: Proceedings of the 11th Hokkaido Symposium on Transfusion Medicine. Ikeda H., ed. Sapporo, Japan, 1999; 73-82.
  217. Holland PV: Old and New Tests: Where will it end? Vox Sang 2000;78 (suppl 2): 67-70.
  218. Brecher ME, Holland PV, Pineda AA, Tegtmeier GE, Yomtovian R: Growth of bacteria in inoculated platelets: implications for bacteria detection and the extension of platelet storage. Transfusion 2000;40:1309-1312.
  219. Kopko PM, Holland PV: Universal leukocyte reduction. Curr Opin Hematol 2000;7:397-401.
  220. Gresens CJ, Holland PV: Other reactions and alloimmunization. In: Blood Safety and Surveillance. Linden JV, Bianco C, eds. New York: M Dekker, Inc. 2001; 71-86.
  221. Usuda S, Okamoto H, Tanaka T, Kidd-Ljunggren K, Holland PV, Miyakawa Y, Mayumi M: Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. J Virol Methods 2000;87:81-89.
  222. Collier AC, Kalish LA, Busch MP, Holland PV, for the Viral Activation Transfusion Study Group: Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. The Viral Activation Transfusion Study: A Randomized Controlled Trial. JAMA 2001;285:1592-1601.
  223. Holland PV: Measuring the volume of packed RBCs in donors. Transfusion 2001;41:309-311.
  224. Holland PV, Clark K: Notification and counseling of HIV-positive donors. In: Molecular Biology in Transfusion Medicine. Hisami Ikeda, ed. Proceedings of the 12th Hokkaido Symposium on Transfusion Medicine, Sapporo 2000, pages 189-198.
  225. Kopko PM, Holland PV: Mechanisms of severe transfusion reactions. Transfus Clin Biol 2001;8:278-281.
  226. Kopko PM, Fernando LP, Bonney EN, Freeman JL, Holland PV: HIV transmissions from a window-period platelet donation. Am J Clin Path 2001;116(4):562-566.
  227. Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland, PV: HLA class II antibodies in transfusion-related acute lung injury. Transfusion 2001;41:1244-1248.
  228. Holland, PV: Viral safety of blood transfusion – now and then. Chin J Blood Transfusion 2001 Vol. 14 Supplement 1-4.
  229. Gresens CJ, Holland PV: The disappearance of transfusion-transmitted hepatitis C virus infections in the United States. Clinics in Liver Disease: Advances in Hepatitis C 2001;5:1105-1113.
  230. Janatpour K, Holland PV: Blood support for pediatric surgery. Indian J Ped 2001;68:159-165.
  231. Kuramoto IK, Moriya T, Schoening V, Holland PV: Fluctuation of serum HCV RNA levels in untreated blood donors with chronic HCV infection. J Vir Hep 2002;9:36-42.
  232. Moriya T, Kuramoto IK, Yoshizawa H, Holland PV: Distribution of hepatitis B virus genotypes among American blood donors determined with a preS2 epitope enzyme-linked immunosorbent assay kit. J Clin Micro 2002; 877-880.
  233. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA: Transfusion-related acute lung injury – report of a clinical look-back investigation. JAMA 2002;287:15:1968-1971.
  234. Kopko PM, Holland PV: HIV as a previous emerging virus. Blood Therapies in Medicine 2002;2:55-56.
  235. Holland PV: Pathogen inactivation for blood components. Proceedings: The Third Red Cross and Red Crescent Symposium on Blood Programs in the Asian Region. Securing Safe Blood (III) 2002; 191-194.
  236. Corash L, Holland PV: Inactivation of infectious pathogens. In: The Dawn of Transfusion Medicine in the New Century, Proceedings of the 13th Hokkaido Symposium on Transfusion Medicine, Sapporo 2001; 185-199.
  237. Janatpour K, Paglieroni TG, Schuller L, Foley K, Rizzardo T, Holland PV: Interpretation of atypical patterns encountered when using a flow cytometry-based method to detect residual leukocytes in leukoreduced red blood cell components. Clinical Cytometry 2002; 50:254-260.
  238. Galel SA, Strong DM, Tegtmeier GE, Holland PV, Kuramoto IK, Kemper M, Pietrelli L, Gallarda J: Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays. Transfusion 2002; 42:1507-1513.
  239. Janatpour, K, Holland PV: Noninfectious serious hazards of transfusion. Current Hematology Reports 2002; 1:149-155.
  240. Hutchinson K, Kopko PM, Muto KN, Tuscano J, O’Donnell RT, Holland PV, Richman C, Paglieroni TG, Wun T: Early diagnosis and successful treatment of transfusion-associated graft-versus-host disease with autologous peripheral stem cell transplantation. Transfusion 2002; 42:1567-1572.
  241. Kopko PM, Paglieroni TG, Popovsky MA, Muto KN, MacKenzie MR, Holland PV: TRALI: correlation of antigen-antibody and monocyte activation in donor-recipient pairs. Transfusion 2003; 43:177-184.
  242. Holland PV: The safest unit of blood could kill you. Proceedings of the 14th Hokkaido Symposium on Transfusion Medicine Sapporo 2002, Blood Products in Next Generation; 52-60.
  243. Nollet KE, Holland PV: Toward a coalition against transfusion-associated GVHD. Transfusion 2003;43:1655-1657.
  244. Nollet KE, Holland PV: Recent progress in transfusion-associated graft-vs-host disease. Indian Journal of Hematology & Blood Transfusion 2003; Vol XXI : Suppl 3, 114-118.
  245. Gresens CJ, Holland PV: Universal leukoreduction in the USA. Indian J Hem & Blood Transfusion 2003; Suppl 3, 109-113.
  246. Paglieroni TG, Janatpour K, Gosselin R, Crocker V, Dwyre DM, MacKenzie MR, Holland PV, Larkin EC: Platelet function abnormalities in qualified whole-blood donors: effect of medication and recent food intake. Vox Sang 2004; 86: 48-53.
  247. Janatpour KA, Paglieroni TG, Crocker VL, DuBois D, Holland PV: Visual assessment of hemolysis in red blood cell units and segments can be deceptive. Transfusion 2004;44:984-989.
  248. Utter GH, Owings JT, Tzong-Hae L, Paglieroni, TG, Reed WF, Gosselin, RC, Holland PV, Busch MP: Blood transfusion is associated with donor leukocyte microchimerism in trauma patients. J Trauma 2004; 57: 702-7.
  249. Gresens CJ, Flynn NM, Simon NF, Jensen HM, Holland PV: Transfusion (and related secondary) transmission of hepatitis A virus. Proceedings of the 11th International Symposium on Viral Hepatitis and Liver Disease. Editors: AR Jilbert, EV Lgrgacic, K Vickery, CJ Burrell, YE Cossart. Australian Centre for Hepatitis Virology; 2004: pp. 471-472.
  250. Kleinman S, Strong DM, Tegtmeier G, Holland PV, Gorlin J, Cousins C, Chiacchierini RP, Pietrelli L: Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS Ampliscreen HBV test. Transfusion 2005;45:1247-1257.
  251. Lee T-H, Paglieroni T, Utter G, Chafets D, Gosselin RC, Reed W, Owings JT, Holland PV, Busch MP: High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion 2005;45:1280-1290.
  252. Janatpour K, Denning L, Nelson K, Betlach B, MacKenzie M, Holland P: Comparison of X-ray vs. gamma irradiation of CPDA-1 red cells. Vox Sang 2005;89:215-219.
  253. Utter GH, Owings JT, Lee T-H, Paglieroni TG, Reed WF, Gosselin RC, Holland PV, Busch MP: Microchimerism in transfused trauma patients is associated with diminished donor-specific lymphocyte response. J Trauma 2005;58:925-932.
  254. Comanor L, Holland P: Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006;91:1-12.
  255. Janatpour K, Holland PV: A Brief History of Blood Transfusion. Blood Banking and Transfusion Medicine Basic Principles and Practice. Hillyer, Silberstein, Ness, Anderson, Roback (Eds). Churchill Livingstone Elsevier 2007, Philadelphia, PA. 3-11.
  256. McCarthy LJ, Emmett TW, Smith DS, Holland PV: Evidence-based medicine in transfusion medicine: an update. ISBT Science Series 2007;2:35-40.
  257. Janatpour KA, Kalmin ND, Jensen HJ, Holland PV: Clinical outcomes of ABO-incompatible RBC transfusions. Am J Clin Path 2008;129:276-281.
  258. Holland PV: Donor deferral registries: an ineffective system whose time is passed . Transfusion 2008;48:6-7.
  259. Holland PV: Selling blood vs. donating blood. Vox Sang 2008;94:171.
  260. Dwyre DM and Holland PV. Hepatitis viruses. in Transfusion Microbiology Eds. JJ Barbara, FM Regan, MC Contreras. Cambridge University Press, Cambridge UK 2008, 9-23.
  261. Dwyre DM and Holland PV. Transfusion-associated graft-versus-host disease. Vox Sang 2008;95:85-93.
  262. Jensen HM, Galante JM, Kysar PE, Tolstikov VV, Reddy KJ, Holland PV. TRALI is due to pulmonary venule damage from leucocytes with cholesterol crystal formation. Vox Sang 2010;98:130-137.
  263. Tran S, Lewalski EA, Dwyre DM, Hagar Y, Beckett L, Janatpour KA, Holland PV. Does donating blood for the first time during a national emergency create a better commitment to donating again? Vox Sang 2010;98:e219-224.
  264. Dwyer DM, Fernando LP, Holland PV. Hepatitis B, Hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011;100:92-8.
  265. Marcin JP, Gosselin R, Holland PV. Hypercoagulability among pediatric patients with diabetic ketoacidosis: the clot thickens. Ped Crit Care Med 2013;14:325-6.
  266. Van Ness M, Jensen H, Adamson GN, Kysar PE, Holland PV. Neutrophils contain cholesterol crystals in transfusion-related acute lung injury (TRALI). Am J Clin Pathol 2013;140:170-76.